User Login  



Trends in Medicinal Chemistry

6th December 2018
Friends House, Euston Road, London

08.30 Registration and coffee
09.25 Welcome and introduction - David Pryde, Curadev Pharma Ltd
Session 1: Finding and Modulating New Targets
Chair: David Pryde, Curadev Pharma Ltd
09.30 Mike Hann, GSK, UK
‘PhABits – shining new light on fragment approaches'
10.10 Christian Ottmann, Technische Universiteit Eindhoven, NL
‘Stabilization of PPIs in drug discovery'
10.50 Coffee break
Session 2: Enabling Computational Technologies
Chair: Mo Alavijeh, Pharmidex Pharmaceutical Services Ltd.
11.10 Quentin Perron, IKTOS, FR
‘AI approaches to drug design'
11.50 Peter Coveney, UCL, UK
‘Predicting ligand-protein binding affinities - rapidly, accurately and reliably'
12.30 Lunch, to include the SMR AGM at 13.15 for SMR members
Session 3: New modalities and delivering them
Chair: Mo Alavijeh, Pharmidex Pharmaceutical Services Ltd.
13.30 Steve Hood, GSK, UK + Peter Watson, University of Cardiff, UK
‘Public Private Partnerships - what’s in it for industry, academia and patients?'
14.10 Garrick Smith, Nuevolution, DK
‘Development of small molecule inhibitors of IL17A/IL17RA identified from DNA Encoded Libraries'
14.50 Coffee break
Session 4: Peptide Drug Discovery
Chair: Mike Hann, GSK
15.10 Thomas Vorherr, Novartis, CH
‘Discovering peptide drugs'
15.50 Laurent Knerr, AZ, SE
‘Design and application of novel peptide conjugates for targeted delivery approaches'
16.30 Closing comments and end of meeting - Mike Hann, GSK


Back to Menu

Sponsored by